Arcus Biosciences (RCUS) president discloses trust share sales and holdings

Rhea-AI Filing Summary

Arcus Biosciences president Juan C. Jaen reported indirect sales of Arcus Biosciences common stock held by a trust associated with him. On January 5, 2026, the trust sold 29,670 shares at a weighted average price of $21.34, 2,053 shares at a weighted average price of $22.34, and 100 shares at $23.20, under a Rule 10b5-1 trading plan adopted on August 8, 2025.

Following these transactions, the trust continued to hold 922,240 shares of Arcus Biosciences common stock. Jaen also reported 346,012 shares held directly, which include the unvested portion of his restricted stock unit grants.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jaen Juan C.

(Last) (First) (Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S		29,670(1)	D	$21.34(2)	924,393	I	By Trust
Common Stock	01/05/2026		S		2,053(1)	D	$22.34(3)	922,340	I	By Trust
Common Stock	01/05/2026		S		100(1)	D	$23.2	922,240	I	By Trust
Common Stock								346,012(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 8, 2025.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.975 to $21.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.04 to $22.985, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

4. Includes the unvested portion of the reporting person's RSU grants.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider stock transactions did Arcus Biosciences (RCUS) disclose?

A trust associated with president Juan C. Jaen sold 29,670, 2,053, and 100 shares of Arcus Biosciences common stock on January 5, 2026 in three separate transactions.

At what prices were the Arcus Biosciences (RCUS) shares sold in this Form 4?

The reported weighted average sale prices were $21.34 for 29,670 shares, $22.34 for 2,053 shares, and $23.20 for 100 shares of common stock.

Were the Arcus Biosciences (RCUS) insider sales made under a Rule 10b5-1 plan?

Yes. The filing states that the sales were effected under a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.

How many Arcus Biosciences (RCUS) shares does the trust hold after these transactions?

After the reported sales, the trust associated with Juan C. Jaen held 922,240 shares of Arcus Biosciences common stock indirectly.

How many Arcus Biosciences (RCUS) shares does Juan C. Jaen hold directly after this Form 4?

The filing reports 346,012 shares of common stock held directly by Juan C. Jaen, which include the unvested portion of his RSU grants.

What is Juan C. Jaen’s role at Arcus Biosciences (RCUS)?

Juan C. Jaen is identified in the filing as an officer of Arcus Biosciences, holding the title of President.